AAPL 255.59 -1.3242% MSFT 430.53 -1.7302% NVDA 137.01 -2.0868% GOOGL 192.76 -1.4519% GOOG 194.04 -1.5525% AMZN 223.75 -1.4534% META 599.81 -0.5867% AVGO 241.75 -1.4713% TSLA 431.66 -4.9479% TSM 201.63 -0.7042% LLY 783.17 -1.3814% V 318.66 -0.7011% JPM 241.205 -0.7958% UNH 509.99 -0.2269% NVO 87.37 -0.3195% WMT 91.66 -1.2178% LVMUY 132.31 -0.1735% XOM 106.48 -0.0094% LVMHF 660.01 -0.7131% MA 532.2 -0.7367%
Last update at 2024-12-27T21:00:00Z
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
Fri 20 Dec 24, 01:00 PMThe Ultimate Biotech Stock to Buy With $500 Right Now
Thu 12 Dec 24, 12:00 AM2 No-Brainer Stocks to Buy Before the End of 2024
Mon 09 Dec 24, 12:00 AMShould You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Thu 05 Dec 24, 12:00 AMGot $500? 1 Biotech Stock to Buy and Hold Forever
Fri 22 Nov 24, 12:00 AM2 Biotech Stocks You Can Buy Hand Over Fist This Month
Fri 08 Nov 24, 12:00 AMIs Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Trading At A 44% Discount?
Mon 21 Oct 24, 11:00 AMThe Smartest Growth Stock to Buy With $500 Right Now
Sat 19 Oct 24, 12:00 AMVertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to Note
Mon 14 Oct 24, 10:00 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 4232.40M | 2730.40M | 3116.80M | 1394.92M | 600.24M |
| Minority interest | - | - | 0.00000M | 0.00000M | -9.79300M |
| Net income | 3322.00M | 2342.10M | 2711.65M | 1176.81M | 2096.90M |
| Selling general administrative | 887.20M | 840.10M | 770.46M | 658.50M | 557.62M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 7850.40M | 6670.20M | 5469.38M | 3615.06M | 2638.06M |
| Reconciled depreciation | 148.30M | 125.60M | 109.52M | 106.94M | 72.42M |
| Ebit | 4307.40M | 2782.10M | 2856.29M | 1197.57M | 590.76M |
| Ebitda | 4345.20M | 2788.80M | 3188.05M | 1457.88M | 663.18M |
| Depreciation and amortization | 37.80M | 6.70M | 331.76M | 260.31M | 72.42M |
| Non operating income net other | -20.20000M | 9.80M | 318.66M | 255.85M | -0.79000M |
| Operating income | 4307.40M | 2782.10M | 2856.29M | 1197.57M | 635.15M |
| Other operating expenses | 4565.30M | 4795.40M | 3336.29M | 2960.80M | 2383.63M |
| Interest expense | 54.80M | 61.50M | 58.15M | 58.50M | 34.12M |
| Tax provision | 910.40M | 388.30M | 405.15M | 218.11M | -1486.86200M |
| Interest income | 144.60M | 4.90M | 22.24M | 63.68M | 33.50M |
| Net interest income | 89.80M | -56.60000M | -35.91200M | 5.18M | -34.11900M |
| Extraordinary items | - | - | - | - | 1560.00M |
| Non recurring | 115.50M | - | - | - | 28.82M |
| Other items | - | - | - | - | - |
| Income tax expense | 910.40M | 388.30M | 405.15M | 218.11M | -1486.86200M |
| Total revenue | 8930.70M | 7574.40M | 6205.68M | 4162.82M | 3047.60M |
| Total operating expenses | 3485.00M | 3891.20M | 2599.99M | 2413.04M | 1974.09M |
| Cost of revenue | 1080.30M | 904.20M | 736.30M | 547.76M | 409.54M |
| Total other income expense net | -75.00000M | -51.70000M | 260.51M | 197.35M | -29.60600M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 3322.00M | 2342.10M | 2711.65M | 1176.81M | 2087.10M |
| Net income applicable to common shares | 3322.00M | 2342.10M | 2711.65M | 1176.81M | 2096.90M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 22730.20M | 18150.90M | 13432.50M | 11751.81M | 8318.47M |
| Intangible assets | 839.90M | 603.60M | 400.00M | 400.00M | 400.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 620.50M | 74.40M | 187.20M | 308.35M | 213.51M |
| Total liab | 5149.80M | 4238.20M | 3332.50M | 3064.99M | 2233.22M |
| Total stockholder equity | 17580.40M | 13912.70M | 10100.00M | 8686.82M | 6085.24M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 2928.50M | 1877.70M | 1460.00M | 1171.02M | 1024.29M |
| Common stock | 2.60M | 2.60M | 2.50M | 2.60M | 2.59M |
| Capital stock | 2.60M | 2.60M | 2.50M | 2.60M | 2.59M |
| Retained earnings | 10142.40M | 6522.80M | 3200.80M | 858.67M | -1852.97800M |
| Other liab | - | 685.80M | 902.20M | 923.41M | 275.53M |
| Good will | 1088.00M | 1088.00M | 1402.20M | 1402.16M | 1402.16M |
| Other assets | - | 1422.70M | 986.90M | 587.03M | 1199.40M |
| Cash | 10372.30M | 10504.00M | 6795.00M | 5988.19M | 3109.32M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 3547.40M | 2430.60M | 1873.60M | 1560.11M | 1204.52M |
| Current deferred revenue | 170.30M | 159.60M | 171.70M | 191.52M | 62.33M |
| Net debt | -9563.90000M | -9943.00000M | -6238.30000M | -5406.71100M | -2531.95100M |
| Short term debt | 83.70M | 89.40M | 46.90M | 42.43M | 30.29M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 808.40M | 561.00M | 556.70M | 581.48M | 577.37M |
| Other stockholder equity | 7449.70M | 7386.50M | 6880.80M | 7894.03M | 7937.61M |
| Property plant equipment | - | 1455.80M | 1094.10M | 958.53M | 833.28M |
| Total current assets | 14144.20M | 12681.30M | 9014.80M | 7825.03M | 4609.31M |
| Long term investments | 2497.80M | - | - | - | 60.80M |
| Net tangible assets | - | 12221.10M | 8697.80M | 7284.66M | 4683.09M |
| Short term investments | 849.20M | 274.50M | 729.90M | 670.71M | 698.97M |
| Net receivables | 1563.40M | 1442.20M | 1136.80M | 885.35M | 633.52M |
| Long term debt | - | - | - | - | - |
| Inventory | 738.80M | 460.60M | 353.10M | 280.78M | 167.50M |
| Accounts payable | 364.90M | 303.90M | 195.00M | 155.14M | 87.61M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -14.30000M | 0.80M | 15.90M | -68.48000M | -1.97300M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 2.60M | 2.50M | 2.60M | 2.59M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 6522.80M | 3200.80M | 858.67M | -1852.97800M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 796.70M | 1422.70M | 986.90M | 683.31M | 371.10M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 8586.00M | 5469.60M | 4417.70M | 3926.78M | 3709.15M |
| Capital lease obligations | 808.40M | 471.60M | 556.70M | 581.48M | 538.58M |
| Long term debt total | - | - | - | 539.04M | 538.58M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -2079.60000M | 227.30M | -28.90000M | 378.51M | 33.66M |
| Change to liabilities | - | 1162.20M | 354.10M | 598.57M | 188.09M |
| Total cashflows from investing activities | - | -321.10000M | -340.90000M | 99.39M | -1235.31800M |
| Net borrowings | - | -85.50000M | -24.40000M | -29.02400M | -35.00500M |
| Total cash from financing activities | -562.20000M | -67.70000M | -1478.00000M | -505.28100M | 126.77M |
| Change to operating activities | - | 715.00M | 230.40M | 249.73M | 246.32M |
| Net income | 3619.60M | 3322.00M | 2342.10M | 2711.65M | 1176.81M |
| Change in cash | -139.70000M | 3711.90M | 811.20M | 2868.16M | 462.43M |
| Begin period cash flow | 10512.00M | 6800.10M | 5988.90M | 3120.68M | 2658.25M |
| End period cash flow | 10372.30M | 10512.00M | 6800.10M | 5988.85M | 3120.68M |
| Total cash from operating activities | 3537.30M | 4129.90M | 2643.50M | 3253.51M | 1569.33M |
| Issuance of capital stock | - | - | - | - | 343.24M |
| Depreciation | 181.30M | 148.30M | 125.60M | 109.52M | 106.94M |
| Other cashflows from investing activities | - | -343.70000M | -77.00000M | -19.32700M | -1193.53100M |
| Dividends paid | - | - | 102.00M | 264.95M | 10.05M |
| Change to inventory | -322.90000M | -136.40000M | -92.80000M | -132.01400M | -64.04700M |
| Change to account receivables | -84.10000M | -358.60000M | -274.70000M | -223.44400M | -225.58700M |
| Sale purchase of stock | -427.60000M | -172.00000M | -1561.30000M | -739.40700M | -192.01500M |
| Other cashflows from financing activities | -224.30000M | 3.50M | 130.30M | 276.40M | 24.77M |
| Change to netincome | - | 445.60M | 452.70M | 521.39M | 381.89M |
| Capital expenditures | 258.40M | 204.70M | 235.00M | 259.80M | 75.45M |
| Change receivables | - | -358.60000M | -274.70000M | -223.44400M | -225.58700M |
| Cash flows other operating | - | -453.20000M | -263.50000M | -332.15800M | 5.23M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 3741.10M | 824.60M | 2847.61M | 460.79M |
| Change in working capital | -265.70000M | 340.80M | -105.20000M | -54.45400M | -66.10100M |
| Stock based compensation | 581.20M | 491.30M | 441.40M | 429.46M | 360.49M |
| Other non cash items | -42.60000M | 103.40M | -5.80000M | -220.00500M | -176.19600M |
| Free cash flow | 3278.90M | 3925.20M | 2408.50M | 2993.70M | 1493.88M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Inc |
-1.89 0.46% | 408.76 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| NVO Novo Nordisk A/S |
-1.14 1.30% | 86.23 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
2.37 2.74% | 89.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| REGN Regeneron Pharmaceuticals Inc |
-4.28 0.60% | 712.40 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| CSLLY CSL Ltd |
-0.97 1.09% | 87.88 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
50 Northern Avenue, Boston, MA, United States, 02210
| Name | Title | Year Born |
|---|---|---|
| Dr. Jeffrey Marc Leiden M.D., Ph.D. | Exec. Chairman | 1956 |
| Dr. Reshma Kewalramani FASN, M.D. | CEO, Pres & Director | 1973 |
| Mr. Charles F. Wagner Jr. | Exec. VP & CFO | 1968 |
| Mr. Stuart A. Arbuckle B.Sc. | Exec. VP & COO | 1966 |
| Dr. Ourania Tatsis Ph.D. | Exec. VP and Chief Regulatory & Quality Officer | 1971 |
| Ms. Kristen C. Ambrose | Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services | 1977 |
| Dr. David M. Altshuler M.D., Ph.D. | Exec. VP of Global Research & Chief Scientific Officer | 1965 |
| Mr. Mike Tirozzi | SVP and Chief Information & Data Officer | NA |
| Susie Lisa | Sr. VP of Investor Relations | NA |
| Mr. Damian W. Wilmot Esq. | Sr. VP, Chief Risk and Compliance Officer | 1976 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...